Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab

Pérez-García, Carolina; Maymó, Joan; Pérez, Mariola; Bernabé, Miriam Almirall; Abelló, Jordi Carbonell

doi:10.1093/rheumatology/kei220

Cited by 18 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, ATIL presents with mild findings that improve within several months (mean, 2.9 months; range, 1-6 months) after stopping the anti-TNF-α therapy [5]. In our case, the ATIL developed 8 months after therapy, and its manifestations ceased within 3 months after discontinuation of infliximab, which is consistent with previous reports.…”

Section: Discussionsupporting

confidence: 90%

“…A retrospective French national study of patients with rheumatic diseases on anti-TNF-α therapies estimated the incidence ATIL at around 0.19 % for infliximab-treated patients, 0.18 % for etanercept-treated patients, and 0.10 % for adalimumab- [5]. Only one patient was reported to have developed ATIL while receiving certolizumab [2].…”

Section: Discussionmentioning

confidence: 99%

“…No cases were reported with golimumab. As these biologic agents have similar mechanisms of action, it is difficult to understand the differences in the development of ATIL, but one of the hypothesis is that it may be due to differences in bioavailability, the stability of the drug/ TNF complex, and possibly, the development of autoantibodies and antidrug antibodies [5].…”

Section: Discussionmentioning

confidence: 99%

“…BIOGEAS recently issued guidelines for the management of autoimmune diseases associated with anti-TNF-α [4,5]. They recommend that the treatment should be tailored to the severity of individual clinical and immunological presentation.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

Santiago

Rovisco

et al. 2013

Clin Rheumatol

View full text Add to dashboard Cite

Anti-TNF-α therapies are the latest class of medications found to be associated with drug-induced lupus, a distinctive entity known as anti-TNF-α-induced lupus (ATIL) (Williams et al., Rheumatology (Oxford) 48:716-20, 2009; De Rycke et al., Lupus 14:931-7, 2005; De Bandt et al., Clin Rheumatol 22:56-61, 2003). With the widespread use of these agents, it is likely that the incidence of ATIL will increase. The onset of ATIL in patients with rheumatoid arthritis and Crohn's disease has been described, but the literature regarding the occurrence of this entity in patients with ankylosing spondylitis (AS) is scarce (De Bandt et al., Clin Rheumatol 22:56-61, 2003; Ramos-Casals et al., Autoimmun Rev 9:188-93, 2010; Perez-Garcia et al., Rheumatology 45:114-116, 2006). To our knowledge, few reports of switching anti-TNF-α therapy after ATIL in AS have been reported (Akgül et al., Rheumatol Int, 2012). Therefore, it is not clear whether the development of ATIL should prohibit switch to another therapy, since patients may respond to another anti-TNF-α agent (Akgül et al

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

Santiago

Rovisco

et al. 2013

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…[29][30][31][60][61][62][63][64][65][66][67][68][69][70][71][72][73] In rare instances, lupuslike syndromes have been reported in patients treated with TNF inhibitors and in some cases the syndromes resolve on discontinuation of the TNF blocker. [74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92] Conversely, TNF blockers have been used to successfully treat systemic lupus erythematosus. [93][94][95][96] The presence of serum antinuclear antibodies is not specific for systemic lupus erythematosus and by itself is not a contraindication to treatment with TNF inhibitors.…”

Section: Antinuclear Antibodiesmentioning

confidence: 99%